Search Results - "Palo, W."

P.2.f.021 The safety and tolerability of vortioxetine in treating adults with major depressive disorder after 52 weeks of open-label treatment by Baldwin, D.S, Mahableshwarkar, A.R, Chrones, L, Palo, W, Matz, J

Get full text

Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness by Colwell, H H, Hunt, B J, Pasta, D J, Palo, W A, Mathias, S D, Joseph-Ridge, N

“…We evaluated the psychometric properties of a new gout-specific patient reported outcomes questionnaire. The Gout Assessment Questionnaire (GAQ) and the SF-36…”
Get more information

Magnetic resonance imaging in the quantitative assessment of gouty tophi by Schumacher, Jr, H R, Becker, M A, Edwards, N L, Palmer, W E, MacDonald, P A, Palo, W, Joseph-Ridge, N

“…Measurements of tophus size can be important in monitoring the course of gout therapy, as tophus resolution is proposed as one measure of success of treatment…”
Get more information

Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout by Becker, Michael A, Schumacher, H. Ralph, Wortmann, Robert L, MacDonald, Patricia A, Eustace, Denise, Palo, William A, Streit, Janet, Joseph-Ridge, Nancy

“…In this randomized trial of patients with elevated uric acid levels and gout, febuxostat, a new nonpurine selective inhibitor of xanthine oxidase, was compared…”
Get full text

1013 Intranasal doxepin HCl in the treatment of allergic rhinitis by Fink, J., Lawrence, I., Palo, W., Podpora, J.

Get full text

P647 Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series by Zerôncio, M., Blake, A., Rana-Khan, Q., Palo, W., Bhayat, F.

Get full text

DOP024 Vedolizumab clinical and post-marketing safety experience of opportunistic infections by Ng, S.C., Palo, W., Blake, A., Rana-Khan, Q., Bhayat, F.

Get full text

P442 Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience by Feagan, B., Bhayat, F., Khalid, J.M., Palo, W., Blake, A., Shetzline, M., Travis, S.

Get full text

Tophaceous gout: quantitative evaluation by direct physical measurement by H Ralph Schumacher, Jr, Michael A Becker, William A Palo, Janet Streit, Patricia A MacDonald, Nancy Joseph-Ridge

“…OBJECTIVE: The absence of accepted standardized methods for monitoring tophaceous gout limits the ability to track tophus progression or regression. This…”
Get full text

A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: A multicenter, prospective, randomized, investigator-blinded, parallel-group study by Fogarty, Charles M., Cyganowski, Marcia, Palo, William A., Hom, Richard C., Craig, William A.

“…Background: Cefditoren pivoxil is a broad-spectrum cephalosporin that is approved for the treatment of pharyngitis, acute exacerbations of chronic bronchitis,…”
Get full text

Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: Results of a multicenter, prospective, randomized, double-blind study by van Zyl, Louis, Le Roux, Jacobus G., Lafata, John A., Scott Volk, R., Palo, William A., Flamm, Robert, Hom, Richard C.

“…Background: According to recently issued treatment guidelines, appropriate empiric choices for ambulatory patients with community-acquired pneumonia (CAP) are…”
Get full text

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout by Becker, Michael A., Schumacher, H. Ralph, Wortmann, Robert L., MacDonald, Patricia A., Palo, William A., Eustace, Denise, Vernillet, Laurent, Joseph‐Ridge, Nancy

“…Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was…”
Get full text